|View printer-friendly version|
Spring Bank to Present Pre-Clinical Data on Its Novel STING Antagonist Program at The Autoimmunity Conference
“Aberrant activation of the STING pathway is believed to cause certain autoimmune and inflammatory diseases, including Systemic Lupus Erythematosus (SLE), Aicardi–Goutières Syndrome, Sjögren’s syndrome and certain other rare diseases,” commented Dr.
Dr. Iyer continued, “The rapid advancement of our novel STING antagonist program is further demonstration of our capabilities at
Spring Bank’s poster presentation at
Details of the poster presentation are as follows:
Following the presentation, the poster will be available on the Publications page of the company’s website.
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.